Dr. Chawla has worked as a health economist for over 25 years. She has extensive experience using economic analyses to support the business objectives of life sciences companies. In her work, Dr. Chawla has assessed the value of therapies to inform health care decision makers. Since joining Analysis Group in 2007, she has specialized in market access and commercial strategy, supported by health care analytics including both retrospective analyses and economic modeling, to assess potential future market outcomes. With her industry experience and training as an economist, Dr. Chawla has helped clients address business challenges associated with product development and commercialization, particularly those related to requirements for coverage and reimbursement. She has led multiple engagements to assist life sciences clients in preparing for evidence-based review in a wide range of therapeutic areas. Recent engagements have included value proposition, evidence strategy, and evidence development to support product launches and ongoing demonstration of value; and forecasting and modeling to support market planning and valuation. Dr. Chawla’s recent publications include an assessment of manufacturers’ investment decisions in weight management drug development. She has served as a reviewer or referee for several journals, including Health Affairs, Health Services Research, the Journal of the American Medical Association, the Journal of Managed Care Pharmacy, and Value in Health. Prior to joining Analysis Group, Dr. Chawla was head of the health economics and outcomes research department at Genentech.
Moving Targets: Strategies to Prepare for Reimbursement Trends and Changes in Payment Policies
10:25 AM - 11:15 AM